Software, and increasingly AI-driven software, is redefining what’s possible in modern healthcare. From clinical decision support tools to remote patient monitoring platforms, software as a medical device (SaMD) is now central to innovation pipelines across the industry. But with that opportunity comes complexity.
Navigating SaMD regulations across global markets, particularly in the United States and the European Union, remains one of the most significant challenges for developers and manufacturers. While both regions aim to ensure safety and efficacy, their approaches to classification, approval pathways, and oversight differ in ways that can materially impact timelines, costs, and go-to-market strategies.
In this article, we’ll break down the key differences in US and EU SaMD regulations, highlight where companies often encounter friction, and outline practical strategies for efficiently achieving compliance in both regions.
What Is SaMD?
Before comparing global frameworks, it’s important to establish a clear understanding of what qualifies as SaMD under current SaMD regulations.
Most regulatory authorities—including the US Food and Drug Administration (FDA)—align with the definition established by the International Medical Device Regulators Forum (IMDRF):
Software intended to be used for one or more medical purposes that performs those purposes without being part of a hardware medical device.
Under SaMD regulations, the determining factor is intended use. Software must perform a medical function such as diagnosing, treating, curing, mitigating, or preventing a disease or condition.
This distinction becomes especially important in edge cases, such as:
- Wellness apps vs. mobile medical apps
- Clinical decision support vs. general reference tools
- Patient monitoring vs. lifestyle tracking
Many companies run into regulatory uncertainty at this stage. Software that appears “medical-adjacent” may not qualify as SaMD under strict regulations, while other applications—particularly those leveraging AI—may be more heavily regulated than expected.
Another key clarification is that software embedded in a medical device is not considered SaMD. Instead, it falls under the regulatory framework governing the hardware device itself. True SaMD operates independently, even if it interfaces with external devices or sensors, and typically runs on general-purpose platforms like smartphones or cloud-based systems.
SaMD vs. MDSW: Terminology Differences
One of the first differences companies encounter when navigating international SaMD regulations is terminology.
- In the US, the FDA uses the term Software as a Medical Device (SaMD)
- In the EU, regulators use Medical Device Software (MDSW)
MDSW is defined under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) as software intended to fulfill a medical device purpose, whether used alone or in combination with other products.
In practice, these terms are largely interchangeable. However, subtle differences in interpretation under regional regulations can influence classification decisions, particularly in borderline cases involving AI or decision-support functionality.
Who Regulates SaMD?
Understanding the governing bodies behind SaMD regulations is critical for building an effective regulatory strategy.
United States
In the US, SaMD regulations are overseen by the FDA. The agency relies on a combination of:
- Risk-based classification frameworks
- Predicate device comparisons
- International standards such as ISO 13485, ISO 14971, and IEC 62304
The FDA has also issued evolving guidance specific to digital health and AI, making US regulations dynamic and continually evolving.
European Union
In the EU, SaMD regulations fall under:
- Medical Device Regulation (MDR)
- In Vitro Diagnostic Regulation (IVDR)
Unlike the centralized FDA model, EU regulations involve multiple Notified Bodies—independent organizations responsible for conformity assessments.
The transition from legacy directives (MDD and IVDD) to MDR and IVDR significantly increased the rigor of EU regulations, particularly around clinical evidence, risk classification, and post-market surveillance.
Key Differences in Classification
Classification is one of the most important—and often misunderstood—components of SaMD regulations.
FDA Classification Approach
Under FDA regulations, devices are categorized into three primary classes based on risk:
- Class I (low risk)
- Class II (moderate risk)
- Class III (high risk)
Classification is typically determined by identifying a predicate device—an existing product with similar intended use and technological characteristics.
Implications:
- Faster pathways for incremental innovation
- Clearer expectations when precedents exist
- Significant challenges for novel or first-of-kind SaMD
If no predicate exists, companies must pursue alternative pathways such as De Novo classification, which can extend timelines under US SaMD regulations.
EU Classification Approach
EU SaMD regulations follow a rule-based system defined in MDR and IVDR. Software is classified into:
- Class I
- Class IIa
- Class IIb
- Class III
Unlike the FDA’s comparative model, EU regulations require companies to systematically evaluate their product against a set of classification rules.
For example:
- Software influencing clinical decisions is often Class IIa or higher
- Software driving critical decisions may be Class IIb or Class III
Implications:
- More structured but less flexible classification process
- Higher likelihood of up-classification
- Greater regulatory burden for many software products
This fundamental difference in SaMD regulations means the same product may fall into different risk classes in the US versus the EU.
Approval Pathways and Timelines
Approval timelines are another area where SaMD regulations diverge significantly.
United States
FDA regulations offer multiple pathways:
- 510(k) clearance (predicate-based)
- De Novo classification (for novel devices)
- Premarket Approval (PMA) for high-risk devices
For lower-risk products, timelines can be relatively fast. However, under US SaMD regulations, novel technologies—especially AI-based tools—can face extended review periods.
Additionally, the FDA may apply enforcement discretion in certain cases, allowing some low-risk software to enter the market without formal approval. While beneficial, uncertainty around this designation can delay decision-making.
European Union
Under EU regulations, most software above Class I requires assessment by a Notified Body.
Key factors impacting timelines:
- Notified Body availability
- Depth of clinical evaluation required
- Potential for up-classification
In practice, EU regulations often result in longer and less predictable approval timelines—frequently extending 6 months or more once a Notified Body is engaged.
Clinical Evidence and Documentation Expectations
One of the most critical differences in SaMD regulations lies in clinical and technical documentation requirements.
FDA Expectations
US SaMD regulations emphasize:
- Substantial equivalence (for 510(k))
- Performance testing and validation
- Increasing focus on real-world evidence for AI/ML
While clinical data is important, FDA regulations may allow for more flexibility when a predicate device exists.
EU Expectations
EU SaMD regulations are generally more stringent, requiring:
- Comprehensive clinical evaluation reports (CERs)
- Strong alignment with intended use and risk classification
- Ongoing post-market clinical follow-up (PMCF)
For many companies, meeting EU regulations requires a significantly higher upfront investment in clinical evidence.
Post-Market Surveillance and Lifecycle Management
Modern SaMD regulations extend well beyond initial approval into post-launch and beyond.
United States
FDA regulations increasingly emphasize:
- Real-world performance monitoring
- Cybersecurity management
- AI/ML lifecycle oversight
The FDA’s evolving digital health framework reflects a shift toward continuous regulation rather than one-time approval.
European Union
EU SaMD regulations mandate:
- Post-Market Surveillance (PMS) plans
- Periodic Safety Update Reports (PSURs)
- Continuous clinical evaluation updates
These requirements make lifecycle management a central component of compliance under EU regulations.
Common Challenges Across Both Regions
Despite their differences, companies face several shared challenges when navigating SaMD regulations globally:
- Ambiguity in classification, especially for AI-driven tools
- Evolving regulatory guidance, particularly for adaptive algorithms
- Resource-intensive documentation requirements
- Alignment between product development and regulatory strategy
Failing to address these challenges early can lead to costly delays and rework.
Strategic Considerations for Global Compliance
To efficiently navigate US and EU SaMD regulations, companies should:
- Start Regulatory Planning Early – Regulatory strategy should begin during product definition, not after development.
- Design for the Strictest Market – Aligning with the more stringent aspects of EU regulations can streamline global approval.
- Leverage International Standards – Standards like ISO 13485, ISO 14971, and IEC 62304 form the backbone of most SaMD regulations.
- Plan for Lifecycle Compliance – Post-market requirements are integral to both US and EU regulations.
- Anticipate AI-Specific Challenges – Adaptive algorithms introduce new complexities under evolving SaMD regulations.
Using Experience to Navigate SaMD Regulations
Successfully navigating global regulations requires more than technical compliance—it demands strategic insight, cross-market experience, and proactive planning.
At Sequenex, we specialize in helping digital health and medical software companies align with complex SaMD regulations across the US, EU, and other global markets. Our team brings decades of experience guiding products from early development through regulatory approval and post-market success.
Whether you’re developing a novel AI-driven platform or expanding into new regions, we help you:
- Define the optimal regulatory pathway
- Build compliant documentation from day one
- Minimize delays and unexpected rework
- Accelerate time to market
Designing with SaMD regulations in mind from the outset is one of the most effective ways to reduce risk and improve outcomes.
Final Thoughts on Navigating Global Regulation
As software continues to transform healthcare, understanding the nuances of global SaMD regulations is a competitive advantage you should be using.
While the US and EU share common goals, their regulatory frameworks differ in ways that directly impact product strategy, development timelines, and commercialization success. Companies that take a proactive, informed approach to SaMD regulations are far better positioned to bring safe, effective innovations to market—faster.
To learn more about navigating global SaMD regulations, connect with Sequenex today and discover how we can support your path to regulatory success.
